<?xml version="1.0" encoding="UTF-8"?><marc:collection xmlns:marc="http://www.loc.gov/MARC21/slim">
  <marc:record>
    <marc:leader>00000nam##2200000za#4500</marc:leader>
    <marc:controlfield tag="001">9.643585</marc:controlfield>
    <marc:controlfield tag="003">CaOODSP</marc:controlfield>
    <marc:controlfield tag="005">20220505163029</marc:controlfield>
    <marc:controlfield tag="007">cr |||||||||||</marc:controlfield>
    <marc:controlfield tag="008">150407|2014||||xxc|||||o    f|0| 0 fre|d</marc:controlfield>
    <marc:datafield tag="020" ind1=" " ind2=" ">
      <marc:subfield code="a">978-0-660-22486-2</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="040" ind1=" " ind2=" ">
      <marc:subfield code="a">CaOODSP</marc:subfield>
      <marc:subfield code="b">fre</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="043" ind1=" " ind2=" ">
      <marc:subfield code="a">n-cn---</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="086" ind1="1" ind2=" ">
      <marc:subfield code="a">HP40-1/4-1-2014F-PDF</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="110" ind1="2" ind2=" ">
      <marc:subfield code="a">Agence de santé publique du Canada.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="245" ind1="1" ind2="0">
      <marc:subfield code="a">Déclaration supplémentaire concernant les recommandations liées au diagnostic, à la prise en charge et au suivi des atteintes inflammatoires pelviennes : </marc:subfield>
      <marc:subfield code="h">[ressource électronique]</marc:subfield>
      <marc:subfield code="b">lignes directrices canadiennes sur les infections transmissibles sexuellement </marc:subfield>
    </marc:datafield>
    <marc:datafield tag="260" ind1=" " ind2=" ">
      <marc:subfield code="a">Ottawa - Ontario : </marc:subfield>
      <marc:subfield code="b">Agence de santé publique du Canada </marc:subfield>
      <marc:subfield code="c">Mars 2014.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="300" ind1=" " ind2=" ">
      <marc:subfield code="a">2p.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="590" ind1=" " ind2=" ">
      <marc:subfield code="a">14-36</marc:subfield>
      <marc:subfield code="b">2014-09-05</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="691" ind1="0" ind2="7">
      <marc:subfield code="a">Maladie transmise sexuellement</marc:subfield>
      <marc:subfield code="2">gcpds</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="775" ind1="0" ind2="8">
      <marc:subfield code="t">Supplementary statement for recommendations related to the diagnosis, management, and follow-up of pelvic inflammatory disease : </marc:subfield>
      <marc:subfield code="w">(CaOODSP)9.699606</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="856" ind1="4" ind2="0">
      <marc:subfield code="a">http://publications.gc.ca</marc:subfield>
      <marc:subfield code="q">PDF</marc:subfield>
      <marc:subfield code="s">141 Ko</marc:subfield>
      <marc:subfield code="u">https://publications.gc.ca/collections/collection_2014/aspc-phac/HP40-1-4-1-2014-fra.pdf</marc:subfield>
    </marc:datafield>
  </marc:record>
</marc:collection>
